4.7 Article

A novel and hybrid composite transposon at the origin of acquisition of blaRTG-5 in Acinetobacter baumannii

期刊

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2012.04.002

关键词

beta-Lactamase; Insertion sequence; Genetic context; Transposon

资金

  1. INSERM [U914]
  2. UMR Universite Paris-Sud (France)
  3. European Community (TEMPOtest-QC) [HEALTH-2009-241742]

向作者/读者索取更多资源

The genetic context of the gene coding for the novel variant of the class A beta-lactamase RTG-5 (CARB-14), exhibiting two amino acid substitutions compared with the closest RTG-3 enzyme, was analysed in a clinical isolate of Acinetobacter baumannii. This novel variant exhibited a narrow-spectrum profile, as observed for RTG-3. Sequence analysis of the region flanking the 5' end of bla(CARB-14) identified a novel insertion sequence ISAba21 belonging to the IS3 family. Downstream of bla(CARB-14), another insertion sequence belonging to the IS3 family named ISAba14 was identified. Analysis of the left-end extremity of ISAba21 and the right-end extremity of ISAba14 identified direct repeat sequences of 3 bp, likely being the signature of a transposition process. This is one of the few examples of a composite transposon made of different insertion sequences bracketing a gene coding for this novel carbenicillinase. (C) 2012 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Infectious Diseases

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales

Agnes B. Jousset, Sandrine Bernabeu, Cecile Emeraud, Remy A. Bonnin, Alexandra Lomont, Jean Ralph Zahar, Audrey Merens, Christophe Isnard, Nathalie Soismier, Eric Farfour, Vincent Fihman, Nicolas Yin, Olivier Barraud, Herve Jacquier, Anne-Gaelle Ranc, Frederic Laurent, Stephane Corvec, Louise Ruffier d'Epenoux, Emmanuelle Bille, Nicolas Degand, Chloe Plouzeau, Thomas Guillard, Vincent Cattoir, Asaf Mizrahi, Antoine Grillon, Frederic Janvier, Cecile Le Brun, Marlene Amara, Mathilda Bastide, Alban Lemonnier, Laurent Dortet

Summary: This study aimed to provide susceptibility data on a large series of Enterobacterales since the revision of EUCAST categorization break-points in 2020. The results showed that Ceftolozane-tazobactam (C/T) had a susceptibility rate of 88% in Enterobacterales infections, with higher susceptibility in 3GC-resistant strains and lower susceptibility in CRE strains. This prospective study highlights the importance of C/T in the treatment of infections.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2023)

Article Microbiology

Emergence of Carbapenemase-Producing Hypervirulent Klebsiella pneumoniae in Switzerland

Otavio Hallal Ferreira Raro, Patrice Nordmann, Manuel Dominguez Pino, Jacqueline Findlay, Laurent Poirel

Summary: There is an increasing occurrence of multidrug-resistant (MDR) and hypervirulent (hv) Klebsiella pneumoniae (MDR-hvKp) convergent clones. These strains can cause difficult-to-treat infections and have a higher mortality rate in healthy adults. This study in Switzerland identified a rate of 9.0% K. pneumoniae with a virulence genotype, producing carbapenemase and recovered from rectal swabs, urine, and blood. The presence of alarming MDR-hvKp and MDR nonhypervirulent K. pneumoniae (MDR-nhv-Kp) isolates highlights the need for surveillance networks to track and monitor their spread.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Article Infectious Diseases

Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25

Jacqueline Findlay, Laurent Poirel, Maxime Bouvier, Valeria Gaia, Patrice Nordmann

Summary: Carbapenem-resistant Enterobacterales, including KPC-producing Klebsiella pneumoniae, pose a major threat to public health due to their rapid spread. Ceftazidime-avibactam, a beta-lactam/beta-lactamase inhibitor combination, has shown excellent activity against multidrug-resistant KPC-producing Enterobacterales strains. However, there is an increasing occurrence of CAZ-AVI-resistant K. pneumoniae isolates, mainly due to the emergence of KPC variants that confer resistance to CAZ-AVI but retain carbapenem resistance.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2023)

Letter Infectious Diseases

Rapid selection of a cefiderocol-resistant Escherichia coli producing NDM-5 associated with a single amino acid substitution in the CirA siderophore receptor

Agnes B. Jousset, Corentin Poignon, Seher Yilmaz, Alexandre Bleibtreu, Cecile Emeraud, Delphine Girlich, Thierry Naas, Jerome Robert, Remy A. Bonnin, Laurent Dortet

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Infectious Diseases

Emergence of KPC-3-and OXA-181-producing ST13 and ST17 Klebsiella pneumoniae in Portugal: genomic insights on national and international dissemination

Rita Elias, Anton Spadar, Antoni P. A. Hendrickx, Remy A. Bonnin, Laurent Dortet, Margarida Pinto, Jody E. Phelan, Isabel Portugal, Susana Campino, Gabriela Jorge da Silva, Taane G. Clark, Aida Duarte, Joao Perdigao

Summary: This study characterized the genomic diversity and international dissemination of CRKP strains from tertiary care hospitals in Lisbon, Portugal. Two genomic clusters, ST13/GC1 and ST17/GC2, were identified. Additionally, an emerging OXA-181/ST17-producing strain in Portugal and the ongoing international dissemination of a KPC-3/ST13-producing clone were highlighted.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Infectious Diseases

Resist Acineto rapid immunological test for the detection of acquired carbapenemase producers among Acinetobacter spp

Maxime Bouvier, Auriane Kerbol, Jacqueline Findlay, Samanta Freire, Laurent Poirel, Patrice Nordmann

Summary: Resist Acineto is a novel immunochromatographic test for detecting the major acquired carbapenemases (OXA-23, OXA-40, OXA-58, and NDM) in Acinetobacter spp. This test is rapid and easy to perform, and it has shown excellent specificity and sensitivity with 100% positive and negative predictive values in both cases.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2023)

Article Infectious Diseases

Dissemination of ArmA- and OXA-23-co-producing Acinetobacter baumannii Global Clone 2 in Switzerland, 2020-2021

Jacqueline Findlay, Patrice Nordmann, Maxime Bouvier, Auriane Kerbol, Laurent Poirel

Summary: This study investigated the spread and emergence of A. baumannii clones co-producing OXA-23 and ArmA in Switzerland. The majority of the isolates were obtained from infections and belonged to the high-risk GC-2 clone. Monitoring and control of these MDR A. baumannii strains are crucial to prevent further spread.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii

Otavio Hallal Ferreira Raro, Maxime Bouvier, Auriane Kerbol, Jean-Winoc Decousser, Laurent Poirel, Patrice Nordmann

Summary: The study developed a rapid test for the detection of Acinetobacter baumannii susceptibility to the antibiotic cefiderocol. The test showed high sensitivity and specificity and significantly reduced the time required compared to current methods.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland

Patrice Nordmann, Maxime Bouvier, Laurent Poirel

Summary: Carbapenemase-producing Enterobacterales (CPE) are a major health concern globally, with limited therapeutic options in Switzerland. This study evaluated the susceptibility of CPE isolates recovered in Switzerland from 2018 to 2020 to novel β-lactam/β-lactamase inhibitor combinations, including ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam. The majority of clinical CPE isolates were Klebsiella pneumoniae and Escherichia coli, and the distribution of carbapenemases varied. The study found that meropenem-vaborbactam had the highest susceptibility among the three combinations, followed by ceftazidime-avibactam and imipenem-relebactam. These findings can help optimize first-line therapy for CPE infections.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern

Christophe Le Terrier, Patrice Nordmann, Chloe Buchs, Doris Yoong Wen Di, Gian Maria Rossolini, Roger Stephan, Mariana Castanheira, Laurent Poirel

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Infectious Diseases

Role of bla(TEM) and OmpC in the piperacillin-tazobactam resistance evolution by E. coli in patients with complicated intra-abdominal infection

Lydia Galvez-Benitez, Jose Manuel Ortiz de la Rosa, Angel Rodriguez-Villodres, Carlos S. Casimiro-Soriguer, Irene Molina-Panadero, Rocio Alvarez-Marin, Remy A. Bonnin, Thierry Naas, Jeronimo Pachon, Jose Miguel Cisneros, Jose Antonio Lepe, Younes Smani

Summary: This study aimed to identify the mechanisms underlying Piperacillin-tazobactam resistance (P/T-R) in Escherichia coli. The results showed that P/T-R isolates had a higher copy number of the bla(TEM) gene, generated by three different genetic events. In addition, reduced expression of OmpC was observed in two P/T-R strains. This study provides important insights into the acquisition of P/T-R in E. coli, which is crucial for effective treatment and prevention of resistant microorganisms.

JOURNAL OF INFECTION (2023)

Article Microbiology

Pharmacokinetic/pharmacodynamic analysis of ceftazidime/avibactam and fosfomycin combinations in an in vitro hollow fiber infection model against multidrug-resistant Escherichia coli

Niklas Kroemer, Lisa F. Amann, Aneeq Farooq, Christoph Pfaffendorf, Miklas Martens, Jean-Winoc Decousser, Nicolas Gregoire, Patrice Nordmann, Sebastian G. Wicha

Summary: Rational combination therapy can increase efficacy and prevent the emergence of resistance. This study found that the combination of ceftazidime/avibactam and fosfomycin showed strong synergy in suppressing bacterial count and preventing resistance. Clinical evaluations are needed to explore dose reductions and the use of this combination for highly resistant strains.

MICROBIOLOGY SPECTRUM (2023)

Article Infectious Diseases

Plasmid-mediated fosfomycin resistance in Escherichia coli isolates of worldwide origin

Jacqueline Findlay, Roberto Sierra, Otavio Hallal Ferreira Raro, Marta Aires-de-Sousa, Diego O. Andrey, Patrice Nordmann

Summary: This study analysed a collection of E. coli strains harbouring acquired fosA genes and found high-level resistance to fosfomycin. The strains also carried other antibiotic resistance genes and were capable of transmission through conjugation.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2023)

Review Infectious Diseases

Lenacapavir: A novel injectable HIV-1 capsid inhibitor

Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman

Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)

Article Infectious Diseases

Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri

Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)